Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buprenorphine/naloxone sublingual - Indivior

Drug Profile

Buprenorphine/naloxone sublingual - Indivior

Alternative Names: Naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone; Suboxone film; SUBOXONE® Tablet

Latest Information Update: 07 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Aquestive Therapeutics; Indivior; Reckitt Benckiser Pharmaceuticals
  • Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Opioid-related disorders

Most Recent Events

  • 31 Dec 2022 Registered for Opioid-related disorders (In adolescents, In adults) in European Union prior to December (Sublingual)
  • 31 Dec 2022 Registered for Opioid-related disorders in Australia prior to December (Sublingual)
  • 24 Oct 2022 United States District Court of Pennsylvania dismisses litigation filed against Aquestive Therapeutics and Indivior by group of States’ Attorneys General in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top